Objective: This study evaluated the outcome of intensity-modulated radiation therapy with simultaneous integrated boost and concurrent chemotherapy for nasopharyngeal cancer. Methods: We analyzed 53 consecutive nasopharyngeal cancer patients who received definitive treatment using intensity-modulated radiation therapy with simultaneous integrated boost and cisplatin-based concurrent chemotherapy. Forty-six patients were treated with concurrent chemoradiation and seven patients with induction chemotherapy plus concurrent chemoradiation. The gross tumor (PTV 70 ) received 69.96 Gy (2.12 Gy/fraction), high-risk subclinical disease (PTV 60 ) received 59.4 Gy (1.8 Gy/fraction) and low-risk subclinical disease (PTV 56 ) received 56.1 Gy (1.7 Gy/fraction) in 33 fractions. Twenty-eight patients were treated with step-and-shoot intensity-modulated radiation therapy and 25 patients with helical tomotherapy. Dosimetric parameters were compared between the two modalities. Results: The median treatment duration was 49 days (range: 41 -65 days). The complete response rate was 92.5%. Three local, two regional, one locoregional and seven distant failures were observed. With the median follow-up of 41 months (range: 8-89 months), the 3-and 5-year local control, locoregional control, disease-free survival and overall survival rates were 91.8 and 91.8%; 87.6 and 87.6%; 77.5 and 70.5%; and 86.4 and 82.1%, respectively. Grade 3 mucositis, dermatitis, leucopenia and grade 4 leucopenia were observed in 10, 1, 2 and 1 patient, respectively. No grade 3 or higher xerostomia occurred. Helical tomotherapy significantly improved dosimetric parameters including the maximum dose, volume receiving .107% of the prescribed dose and uniformity index (D 5 /D 95 ). Conclusions: Intensity-modulated radiation therapy with simultaneous integrated boost with concurrent chemotherapy is a safe and effective treatment modality for nasopharyngeal cancer. Helical tomotherapy has a dosimetric advantage over step-and-shoot intensitymodulated radiation therapy in a clinical setting.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) has characteristics distinguishable from other head and neck cancers (HNCs) with respect to epidemiology, clinical features, treatment strategies and response to therapy. NPC is highly endemic in Southeast Asia, with the predominance of the nonkeratinizing undifferentiated (WHO type IIb) tumor histology (1) . Although NPC is radiosensitive and the addition of chemotherapy added survival advantage in locoregionally advanced NPC (2, 3) , conventional radiotherapy (RT) still resulted in relatively frequent local failures with a 5-year local control rate among patients with T3/T4 NPC ranging from 69 to 79% (4, 5) . Local control for NPC is strongly correlated with the radiation dose delivered to the tumor. In a series of 107 patients with NPC, local control was significantly improved when .67 Gy was delivered to the tumor (6) . At many centers, intensity-modulated radiation therapy (IMRT) has become the standard RT technique for treating NPC. IMRT provided better tumor coverage, with a greater percentage of the target volume receiving the planned prescription dose than a conventional 3D conformal plan (7, 8) , and published clinical outcomes demonstrated that IMRT could produce high local and regional control rates in the treatment of NPC (9, 10) .
Simultaneous integrated boost (SIB) technique delivers various fractional doses to different target volumes in a single phase plan. Incorporating moderate hypofractionation is advantageous in that the reduced overall treatment time can counteract the accelerated tumor repopulation and a larger fractional dose is more effective in eliminating the cancer stem cells, which are intrinsically more radioresistant (11, 12) . However, hypofractionation and SIB both have a risk of delivering high-dose radiation to adjacent normal organs and these techniques are best incorporated into IMRT, which can deliver highly conformal radiation to the tumor and maximize the therapeutic window. Helical tomotherapy (HT) is a novel and highly accurate apparatus for delivering IMRT with the image-guided support of onboard megavoltage computed tomography (CT). Because of its 3608 arrangement of intensitymodulated narrow beams passing through binary multileaf collimators (MLCs), HT plans can provide equal or better dose distribution compared with conventional step-and-shoot IMRT (ssIMRT) plans. It has been reported that HT provides improved dose homogeneity to the target and avoidance of normal structures when compared with ssIMRT in the treatment of many types of cancers including retroperitoneal sarcoma (13) , endometrial carcinoma (14) , cranio-spinal tumor (15) and HNC (16, 17) . HT also showed a significant dosimetric gain in the conformity index, homogeneity index and sparing of organs at risk (OARs) when compared with ssIMRT in the treatment of NPC (18) .
The current study reports the treatment outcome of 53 NPC patients treated with IMRT-SIB and concurrent chemotherapy and compares dosimetric parameters between ssIMRT and HT in a clinical setting.
PATIENTS AND METHODS

PATIENTS
We analyzed 53 consecutive patients with biopsy proven, previously untreated stages IIB -IVB nasopharyngeal cancer who received a definitive treatment using IMRT with concurrent chemotherapy at the Yonsei Cancer Center, Severance Hospital between January 2002 and December 2008. All patients underwent fiberoptic nasopharyngoscopy and biopsy for pathological diagnosis. The initial staging evaluation included a clinical examination and CT and/or magnetic resonance imaging (MRI) of the head and neck, chest radiography, abdominal sonography or CT, complete blood count with differential count and biochemical profile. Some patients underwent positron emission tomography for systemic assessment. Staging of nasopharyngeal cancer was based on the TNM system of the American Joint Committee on Cancer, 6th edition.
RADIATION THERAPY
For CT simulation, patients were immobilized in a supine position with custom head and shoulder Aquaplast masks (Aquaplast, Wycoff, NJ), and CT images were obtained every 3 mm extending from the vertex to 5-cm inferior to the clavicular heads. The target volume and normal tissue structures were contoured on each axial CT slice, supplemented with fused diagnostic MRI and/or PET scans. Both ssIMRT and HT plans followed the same target and normal organ delineation protocol and dose prescriptions. SIB technique was used for treatment planning. The gross target volume (PTV 70 ) consisted of the gross primary tumor, the whole nasopharynx and positive lymph nodes, as defined by MRI and/or CT, plus a 0.5-cm margin. The high-risk subclinical disease (PTV 60 ) encompassed PTV 70 plus a 1.5-cm margin, potential spread of microscopic disease (including the parapharyngeal space, posterior third of nasal cavities and maxillary sinuses, pterygoid processes, base of skull and lower half of sphenoid sinus), and the prophylactic area of the neck (including bilateral retropharyngeal nodes, levels II, III and IV). The low-risk subclinical disease (PTV 56 ) included the remaining levels (IV-VB) of the neck. In cases of induction chemotherapy (IC), disease extents in prechemotherapy MRI images were used for target delineation. OARs outlined in three dimensions included the brainstem, spinal cord, lenses, eyes, optic chiasm, optic nerves, cochlea and parotid glands. PTV 70 received a total dose of 69.96 Gy in daily fractions of 2.12 Gy, PTV 60 received 59.4 Gy in 1.8 Gy per daily fraction and PTV 56 received 56.1 Gy in 1.7 Gy per daily fraction. The dose constraints for OARs were as follows: a maximum dose of 54 Gy for the brainstem, optic nerve and optic chiasm; a maximum dose of 45 Gy for the spinal cord; a maximum dose of 70 Gy for the mandible; a mean dose of ,26 Gy or dose to 50% of the parotid volume (D 50% ) ,30 Gy for the parotid gland and a mean dose of ,50 Gy for the inner ear.
For ssIMRT, inverse planning was performed for each patient using CORVUS, version 5.0 (Nomos Corp., Sewickley, PA) and treatment was delivered using PRIMART (Siemens, CA) linear accelerator with 1-cm MLC. A standard coplanar 7-or 9-field gantry arrangement was used for designing all ssIMRT plans. Beam orientation was carefully chosen to achieve optimal parotid sparing. For HT, inverse planning was performed using the Tomotherapy Hi-Art System, version 2.0 (TomoTherapy, Madison, WI). Other parameters for tomotherapy planning included a field width of 2.5 cm, a pitch of 0.3 (distance traveled by the couch during one complete rotation of the gantry divided by the field width), and a modulation factor of 3.0 (a ratio of the maximum and average number of opening of the leaves in active gantry rotations). Both planning systems used least-square minimization as cost functions. Doses to OARs were optimized on an individual basis by a maximum dose constraints set without compromising the PTV coverage, with at least 95% of the PTV receiving the minimum prescribed dose.
DOSIMETRIC COMPARISON BETWEEN SSIMRT AND HT PLANS
The two planning systems use different algorithms for dose calculation. CORVUS for ssIMRT planning uses finite-sized pencil beam algorithms and the work of Nizin (19) , while the Hi-Art system for HT uses superposition convolution algorithm for dose calculation. We used heterogeneity correction options for both planning systems. The following parameters were chosen for PTV 70 and PTV 60 to evaluate the efficacy of IMRT planning and compare the treatment plans between ssIMRT and HT: a maximum dose (D max ), minimum dose (D min ), PTV receiving .95% of the prescribed dose (V 95% ) and PTV receiving .107% of the prescribed dose (V 107% ). In order to assess the uniformity of both plans, we used a uniformity index (UI), defined as the ratio between repeated every 3 weeks, and followed by the concurrent chemoradiation (CCRT) regimens beginning 3 weeks after the third course of IC. Complete blood counts and blood chemistry were checked at least once a week and before each chemotherapy cycle. Dose modifications were allowed based on blood counts and toxicities from preceding cycles.
FOLLOW-UP
The tumor response was assessed according to the World Health Organization (WHO) criteria, and acute and toxicities according to Radiation Therapy Oncology Group (RTOG) criteria. After completion of treatment, patients were followed up at the first, third and sixth month, and every 6 months thereafter. Physical examination, complete blood count, blood chemistry were performed at each visit, along with head and neck CT or MRI, chest radiography and PET or whole body bone scan every 6 months. Patients were evaluated for treatment response by nasopharyngoscopy and head and neck CT or MRI at the first, third and sixth month after completion of treatment. Biopsy was performed when residual disease or recurrence was suspected.
STATISTICAL ANALYSIS
Local failure-free survival (LFFS), locoregional failure-free survival (LRFFS), disease-free survival (DFS) and overall survival (OS) were measured from the beginning of radiotherapy. Descriptive statistics (mean, median and proportions) were used to characterize the patients, disease and treatment features, as well as toxicity after treatment. The probability of failure due to local disease, distant progression and death were estimated using the KaplanMeier method. An independent t-test was used to compare the dosimetric parameters between ssIMRT and HT. P values of ,0.05 were considered having statistical significance.
RESULTS
PATIENT CHARACTERISTICS
The median follow-up periods were 41 months (range: 8 -89). WHO, World Health Organization; CCRT, concurrent chemoradiation; IC þ CCRT, induction chemotherapy followed by CCRT; CR, complete remission; PD, progressive disease; CRT, chemoradiation; DOD, died of disease; AWD, alive with disease; NED, no evidence of disease.
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(range: 41 -65 days). Five patients experienced a treatment break of 4 -7 days due to acute mucositis, two patients experienced 4 and 7 days of a treatment break due to acute dermatitis, and one patient rested for 2 weeks due to neutropenic fever. Acute and late toxicity by site and grade according to the RTOG criteria are listed in Table 5 . For acute toxicity, Grade 3 mucositis, dermatitis and leucopenia were observed in 10, 1 and 2 patients, respectively. Only one patient suffered Grade 4 leucopenia due to chemotherapy. No other Grade 4 acute toxicity was observed. For late toxicity, 14 patients suffered Grade 2 xerostomia. One patient died of massive bleeding from the treatment site 8 months after CCRT. He had been initially diagnosed of T4N2 disease with the left carotid artery invasion and bilateral lymph node metastases including the left level II lymph nodes.
SSIMRT VERSUS HT Table 3 shows the comparison of DVH parameters between the two groups of patients who were treated with ssIMRT (n ¼ 28) and HT (n ¼ 25 Jpn J Clin Oncol 2012;42 (12) 1157 were statistically significant. Comparison of the dose distribution for OARs showed no significant differences between the two modalities, except for D max to the left inner ear and D mean to the left parotid gland, for which ssIMRT was superior (Table 4) . HT showed a trend for improved dermatitis and xerostomia, although the differences were not significant between ssIMRT and HT (Table 5 ). Table 6 shows the comparison of clinical parameters and treatment outcomes among patients treated by ssIMRT and HT. N3 stage was more frequently found among the patients treated with HT (2 vs. 11%, P ¼ 0.028), and more patients were treated with IC þ CCRT in the HT group (2 vs. 11%, P ¼ 0.028). The rates of 5-year local control, locoregional control, diseasefree survival and overall survival between ssIMRT and HT were 93 vs. 89%, 89 vs. 85%, 77 vs. 66% and 85 vs. 83%. The differences were not statistically significant.
DISCUSSION
NPC is primarily treated by radiation alone or CCRT and locoregional control through optimized radiation treatment remains an important goal. IMRT allows the delivery of increased dose of radiation to the tumor with a high degree of conformity, while sparing adjacent critical normal organs. IMRT is highly effective in delivering SIB for HNC cases.
Convenience of a single-phase planning is not the only advantage of IMRT-SIB. The true advantage is in increasing the therapeutic ratio by permitting the differential delivery of escalated daily fraction sizes specifically to the gross disease and standard fraction sizes to the electively treated clinical target volumes, while effectively sparing adjacent critical organs. IMRT-SIB also allows greater conformity compared with other IMRT techniques. In a plan comparison study (20) , IMRT-SIB achieved improved normal tissue sparing compared with sequential delivery of IMRT boost after either whole neck IMRT or conventional fields. The potential role of IMRT-SIB in improving local control through a moderate acceleration of the treatment has been identified in several HNC studies including nasopharyngeal cancer (20) (21) (22) (23) ).
In the current study, IMRT-SIB was used to treat all patients. 1158 SIB-IMRT with concurrent chemotherapy for NPC Forty-nine patients (92.5%) showed a complete clinical and radiographic response at 3 months after initial treatment and 2 patients showed a partial response. The 3-and 5-year local control and locoregional control rates were 91.8 and 91.8%, and 87.6 and 87.6%, respectively, showing the durable effect of treatment on disease control. The result of the current study is comparable to 2 -4-year local control rates of 88 -98% in the other SIB-IMRT studies for nasopharyngeal cancer (10, 21, 24, 25) and significantly higher than 2-year local control of 54 -67% from other clinical trials involving delayed concomitant boost for HNC treatment (26, 27) . IMRT-SIB is advantageous with respect to counteracting the effects of accelerated tumor repopulation through several mechanisms. It had been demonstrated that the prolongation of the overall treatment time in laryngeal cancer may result in a loss of local control of 1% per extra day (28) . Moderate hypofractionation through SIB shortens the overall treatment time by several days or up to 1 week, and patients will benefit from improved local control without significantly increased toxicity. Early initiation of boost schedule may also improve local control, as IMRT-SIB allows the delivery of the boost dose from the beginning of radiotherapy. Terhaard et al. (29) demonstrated that a concomitant boost in week 3 compared with a boost in week 4 of the treatment schedule improved 3-year local control rate from 59 to 78%, with a notion that the accelerated repopulation had occurred sooner than expected and was counteracted by an early start of the boost schedule. NPC has a higher tendency of cervical lymph node metastasis compared with other HNCs. The early boost to individual metastatic cervical lymph nodes may account for the high control rate of regional disease in the current study. Another mechanism of improving local control is through more effective killing of cancer stem cells with larger fraction sizes. An increasing amount of evidence suggests that failure to eradicate cancer stem cells leads to tumor recurrence. Cancer stem cells, that are tumorigenic and capable of self-renewal, have been isolated from head and neck squamous cell carcinoma (11) and shown to be more radioresistant (12) . Recently CD44þ cells with biological characteristics of tumor stem cells have been isolated from human NPC cell line (30) .
In the current study, seven patients (13.2%) showed distant metastases at 4 -48 months (median: 21) after treatment, while locoregional failure was observed in six patients (11.3%). The distant metastasis free survival (DMFS) rates of 89.7 and 81.9% at 3 and 5 years, respectively (results not shown), are comparable to the results of other studies involving accelerated RT with concurrent chemotherapy for nasopharyngeal cancer, where 3-year DMFS ranged from 79 to 90% (23, 25) . Although the addition of chemotherapy improves the treatment outcome of locally advanced NPC, toxicities such as hematologic toxicity and oral mucositis increase in the CCRT setting (31) . Our study, however, demonstrated that the use of IMRT was highly effective in reducing acute and late toxicities such as Grade 3 or higher mucositis and xerostomia.
HT is an advanced form of IMRT. While ssIMRT delivers 5 -9 intensity-modulated radiation beams at fixed gantry angles, HT utilizes a system of 3608 rotational gantry and sliding patient couch resulting in the delivery of multiple intensity-modulated beams in a helical motion. Plan comparison studies between conventional IMRT and HT have shown superior dose conformity for PTV and dose sparing of OARs by HT (16, 18, 32) . Lee et al. (18) compared ssIMRT and HT plans for nasopharyngeal cancer patients. SIB technique was used where 72, 64.8 and 54 Gy were prescribed to PTV, elective PTV and clinically negative neck regions, respectively. HT plans significantly improved the conformity index (improvement ratio: 11.9 + 5.5%), homogeneity index (improvement ratio: 8.8 + 1.5%) and sparing of OARs compared with ssIMRT plans. In the current study, 28 patients were treated with ssIMRT and 25 patients with HT. In dosimetric comparison, HT showed the maximum dose to target (D max ) closer to the prescription dose, lower hot-point (V 107% ) and superior UI coverage compared with ssIMRT for both PTV 70 and PTV 60 . The current study is not to show a direct plan comparison between ssIMRT and HT, since the two treatment plans had not been generated on identical patients. However, a single protocol of targeting and dose prescription was used for both ssIMRT and HT planning, and comparison of dosimetric parameters suggested superiority of HT in the clinical setting. Comparison of treatment outcome between ssIMRT and HT showed no significant difference in terms of local and locoregional control and patient survival. However, it is to be noted that the locoregional control rates of ssIMRT and HT were comparable in spite of the higher incidence of N3 disease among the patients treated with HT. We also noted that patients in the HT group did not report increased rate of mucositis despite the fact that most of the IC þ CCRT cases (6/7) belonged to the HT group. We concluded that both ssIMRT and HT are highly effective in tumor control and sparing of normal organs for the treatment of NPC patients. Target volumes of more complicated shapes, stricter dose constraints for normal organs and longer follow-up periods are required to discriminate the two IMRT modalities in terms of clinical outcome.
A weakness of the current study is that a variety of chemotherapy schedule was used including three different CCRT regimens and IC administered in seven patients. However, all patients received concurrent chemotherapy in the current study, and we expect that locoregional control is mostly a result of adequate radiation coverage with concomitant boost through IMRT-SIB. A prospective trial with a uniform protocol of combined modality treatment is required to accurately assess the role of IMRT-SIB in locoregional control of NPC.
Moderately accelerated radiotherapy through IMRT-SIB with concurrent chemotherapy was well tolerated and highly efficacious for the treatment of NPC, resulting in durable locoregional control and minimized toxicity. Further accumulation of clinical data is required to compare treatment outcomes between conventional IMRT and HT.
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